US3891765A - Anti-inflammatory and analgesic L-hydroxyproline derivatives - Google Patents
Anti-inflammatory and analgesic L-hydroxyproline derivatives Download PDFInfo
- Publication number
- US3891765A US3891765A US243397A US24339772A US3891765A US 3891765 A US3891765 A US 3891765A US 243397 A US243397 A US 243397A US 24339772 A US24339772 A US 24339772A US 3891765 A US3891765 A US 3891765A
- Authority
- US
- United States
- Prior art keywords
- acetyl
- product
- hydroxyproline
- proline
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- ABSTRACT This invention is concerned with new therapeutical derivatives of L-hydroxyproline of the formula:
- R represents COCH;,. 7-theophyllinyl-acetyl, pisobutylphenylacetyl or 2,4-dinitrophenyl. and R represents H, or p-isobutyl phenyl acetyl, excluding N-acetyl- 1 -hydroxyproline and N-acetyll hydroxyprolinamide.
- the compounds of the present invention are preabandoned which in turn is a continuation-in-part of 5 pared by condensmg compound of fmmula U.S.. application Ser. No. 756,410, filed Aug. 30, 1968 and now abandoned.
- R represents OH, NH, ONa, mtrifluoromethylanilido or p-trifluoromethylanilido
- R represents COCH 7-theophyllinyl acetyl, pisobutyl phenyl acetyl or 2,4-dinitrophenyl
- R represents a hydrogen atom or a p-isobutyl phenyl acetyl group, exlcuding N-acety-l hydroxyproline, and N-actyl- 1 -hydroxyprolinamide.
- Hal represents an atom of halogen and R is defined as above, at a temperature between 0 and 25C, and if desired the OH is esteritied, and/or the COOH is esterificd or transformed to sodium salt or the amide derivative.
- the acetylization at the nitrogen is effected by reaction with acetic anhydride in an acetic acid medium at the boiling point of the mixture.
- substitution on the nitrogen atom is effected with the chlorides of 7-theophyllinyl acetic acid, or por m-isobutyl phenyl acetic acid, the reaction takes place at low temperatures in the presence of an organic base such as pyridine, triethyl amine.
- Acetylation at the oxygen atom situated in position 4 by the chloride of p-isobutyl phenyl acetic acid may be effected at a low temperature in the presence of pyridine, the reaction being carried out on a compound of formula I already acetylated at the nitrogen.
- the preferred products according to the invention are selected from the group consisting of N-(2,4- dinitrophenyl )-4-hydroxy-L-proline, N-( 7- theophyllineacetyl )-4-hydroxyl-L-proline: N-acetyl-4-hydroxy-L-proline (m-trifluoromethyl anilide): N-acety1-4-hydroxy-L-proline anilide): N-acetyl-0-(4-isobutyl-phenyl-acetyl)-L- hydroxyproline: N-( p-isobutyl-phenyl-acetyl )-4-hyd roxy-L-proline
- N-(2,4- dinitrophenyl )-4-hydroxy-L-proline N-( 7- theophyllineacetyl )-4-hydroxyl-L-proline
- N-acetyl-4-hydroxy-L-proline m-trifluoromethyl anilide
- the acetone is evaporated and the residue heated to reflux in 200 cc of methanol containing 4 g of sodium hydroxide.
- the product has a formula:
- a solution of 400 mg of sodium nitrite in water is added slowly to a solution of N-acetyl-4-hydroxy-L- proline hydrazide l g) in IQ cc of acetic acid (10% by volume) in water at O2C, and the product stirred for 20 minutes at 0-5C.
- a solution of 2 cc of mtrifluoromethyl aniline in 2 cc of pyridine is then added and stirring continued for 30 minutes at O5C, then 2 hours at 20C.
- N-acetyl-4-hydroxy-L-proline (p-trifluoromethylanilide) A solution of 400 mg of sodium nitrite in 2 cc of water is added slowly to a solution of l g of N-acetyl-4- hydroxy-L-proline hydrazide in 10 cc of IO% acetic acid in water at O-2C, the mixture is stirred for 20 minutes at 5C, after which a solution of 2 cc of ptrifluoromethyl aniline in 2 cc pyridine is added and stirring continued for 30 minutes at 05C, and then for 2 hours at 20C.
- the product has the formula:
- the product has the formula:
- N-(p-isobutyl-phenyl-acetyl)-4-hydroxy-L-proline)2 13.1 g of L-hydroxyproline are dissolved in 50 cc of water containing 4 g of sodium hydroxide at ambient temperature. 13 cc of the acid chloride is added fairly quickly, and then a further 50 cc of water containing 4 g of sodium hydroxide. The product is stirred until dissolution is complete, and allowed to stand for 1 hour, and is then acidified with 10% hydrochloric acid. The product is allowed to stand and is then dried.
- the solid product is dissolved in CH,Cl dried over Na SO and concentrated, after which crystallization is carried out by adding hexane.
- the product has the formula:
- the turpentine micro-abscess test technique is described in British Pat. No. 1,246,141. in this test the compounds forming the subject matter of this invention, and particularly PC. 68-9, exert a powerful action as from the 30 mg/kg dose. This action is associated with the reduction of reticulo-histiocytes, collagen fibres, fibroblasts and even the number of neovessels.
- the pharmacological action of the derivatives of hydroxyproline forming the subject matter of this application consists of anti-inflammation action and an analgesic action.
- the various compounds forming the subject matter of this application have to be administered to human beings in doses each containing 0.100 g or 0.200 g of active product, in 3 to 8 doses a day, in any pharmaceutical form, preferably orally in the form of tablets or gelatin-coated pills.
- EXAMPLES of pharmaceutical preparations Excipient quantity sufficient for 1 tablet. 3 to 8 tablets per day in the treatment of inflammatory cough affections of the respiratory passages.
- the productions of the present invention may be used in any conventional acceptable pharmaceutical form for administration via digestive tract or for administration parenterally.
- a pharmaceutical composition suitable for antiinflammatory and analgesic use in dosage unit form comprising from I milligrams to 200 milligrams of a compound having the formula:
- R isselected from the group consisting of acetyl, p-
- R isobutylphenylacetyl and 2,4-dinitrophenyl; R is hydrogen or p-isobutylphenylacetyl with the proviso that when R, is acetyl and R is hydrogen, then R cannot be OH; and a pharmaceutical carrier.
- composition of claim 1 in which the compound is N-acetyl-4-hydroxy-L-proline (ptrifluoromethyl anilide).
- a method of reducing inflammation of connective tissue which comprises the oral or parenteral administration of the composition of claim I to animals in need thereof from three to eight times daily.
- a method of reducing inflammation of human connective tissue which comprises the oral administration of the composition of claim 1 to humans in need thereof from three to eight times daily.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention is concerned with new therapeutical derivatives of L-hydroxyproline of the formula:
IN WHICH R represents OH, NH2, ONa, m-trifluoromethylanilido or p-trifluoromethylanilido; R1 represents -COCH3, 7-theophyllinylacetyl, p-isobutylphenylacetyl or 2,4-dinitrophenyl, and R2 represents H, or p-isobutyl phenyl acetyl, excluding N-acetyl-1hydroxyproline and N-acetyl-1-hydroxyprolinamide. These compounds are useful as analgesic agents and in the treatment of inflammation.
IN WHICH R represents OH, NH2, ONa, m-trifluoromethylanilido or p-trifluoromethylanilido; R1 represents -COCH3, 7-theophyllinylacetyl, p-isobutylphenylacetyl or 2,4-dinitrophenyl, and R2 represents H, or p-isobutyl phenyl acetyl, excluding N-acetyl-1hydroxyproline and N-acetyl-1-hydroxyprolinamide. These compounds are useful as analgesic agents and in the treatment of inflammation.
Description
United States Patent 11 1 Coirre et al.
[ ANTI-INFLAMMATORY AND ANALGESIC L-HYDROXYPROLINE DERIVATIVES [75] Inventors: Paul Coirre; Bertrand Coirre, both of Ville dAvray; Jean-Claude Denis; Jerome Rambaud, Jean Cahn, all of Paris, all of France [73] Assignee: Franco Chimie S.a.r.l., Paris, France [22] Filed: Apr. 12, 1972 [Zl] Appl. No.: 243,397
Related [1.8. Application Data [63] Continuation-impart of Ser. No. 8l.499. Oct. l6, l970. abandoned which is a continuation-in-part of Ser. No. 756,4), Aug. 20, I968. abandoned.
[30] Foreign Application Priority Data Sept. 14, 1967 France 67.12l020 May 16, [968 France 68.152048 [52] US. Cl. 424/274 [5 [1 Int. Cl A6lk 27/00 [58] Field of Search 424/274 56] References Cited OTHER PUBLICATIONS Chemical Abstracts 53:4259d-4260e (1959). Chemical Abstracts 58:3773a (1963).
Chemical Abstracts 58:3765h (I963).
J.A.C.S. 79 pp. l85l92, I957 (Patchett et aL).
I June 24, 1975 Primary Examiner-Albert T. Meyers Assistam Examiner-Leonard Schenkman Attorney, Agent. or FirmWilliam J. Stein; Eugene O. Retter; George W. Rauchfuss, Jr.
[57] ABSTRACT This invention is concerned with new therapeutical derivatives of L-hydroxyproline of the formula:
trifluoromethylanilido or p-trifluoromethylanilido; R represents COCH;,. 7-theophyllinyl-acetyl, pisobutylphenylacetyl or 2,4-dinitrophenyl. and R represents H, or p-isobutyl phenyl acetyl, excluding N-acetyl- 1 -hydroxyproline and N-acetyll hydroxyprolinamide. These compounds are useful as analgesic agents and in the treatment of inflammation.
4 Claims, No Drawings ANTI-INFLAMMATORY AND ANALGESIC L-HYDROXYPROLINE DERIVATIVES This is a continuation-in-part of our copending application Ser. No. 81,499 filed on Oct. 16, 1970, now
DESCRIPTION OF THE PREFERRED EMBODIMENTS The compounds of the present invention are preabandoned which in turn is a continuation-in-part of 5 pared by condensmg compound of fmmula U.S.. application Ser. No. 756,410, filed Aug. 30, 1968 and now abandoned.
BACKGROUND OF THE INVENTION CO-R wherein R H or COCH R H or COCH OH, or NH or with R COOH and R H and corresponding hydrochlorides excluding the following compounds: l-hydroxyproline and its hydrochloride, N-acetyl- 1 -hydroxyproline, O-acetyl- 1 -hydroxyproline and its hydrochloride and l-hydroxyprolinamide and its hydrochloride; which are useful as antiinflammatory agents.
SUMMARY OF THE INVENTION The present application provides derivatives of L- hydroxyproline of the formula:
in which R represents OH, NH, ONa, mtrifluoromethylanilido or p-trifluoromethylanilido; R, represents COCH 7-theophyllinyl acetyl, pisobutyl phenyl acetyl or 2,4-dinitrophenyl; and R represents a hydrogen atom or a p-isobutyl phenyl acetyl group, exlcuding N-acety-l hydroxyproline, and N-actyl- 1 -hydroxyprolinamide.
with a halide Hal R where Hal represents an atom of halogen and R is defined as above, at a temperature between 0 and 25C, and if desired the OH is esteritied, and/or the COOH is esterificd or transformed to sodium salt or the amide derivative.
The acetylization at the nitrogen is effected by reaction with acetic anhydride in an acetic acid medium at the boiling point of the mixture. When the substitution on the nitrogen atom is effected with the chlorides of 7-theophyllinyl acetic acid, or por m-isobutyl phenyl acetic acid, the reaction takes place at low temperatures in the presence of an organic base such as pyridine, triethyl amine.
The products obtained after this actylation at the nitrogen with acetic anhydride or substituted acetic acid chlorides are capable of being transformed into 2carboxamide derivatives by the usual methods or they may also be converted into the sodium salt in the 2 position if desired.
Acetylation at the oxygen atom situated in position 4 by the chloride of p-isobutyl phenyl acetic acid may be effected at a low temperature in the presence of pyridine, the reaction being carried out on a compound of formula I already acetylated at the nitrogen.
The preferred products according to the invention are selected from the group consisting of N-(2,4- dinitrophenyl )-4-hydroxy-L-proline, N-( 7- theophyllineacetyl )-4-hydroxyl-L-proline: N-acetyl-4-hydroxy-L-proline (m-trifluoromethyl anilide): N-acety1-4-hydroxy-L-proline anilide): N-acetyl-0-(4-isobutyl-phenyl-acetyl)-L- hydroxyproline: N-( p-isobutyl-phenyl-acetyl )-4-hyd roxy-L-proline The following examples are given to illustrate the method in accordance with the invention.
EXAMPLE 1 N-( 2,4-dinitrophenyl )-4-hydroxy-L-proline (p-trifluoromethyl- 13.6 g of 2,4-dinitrofluorobenzene are added drop by drop to 13.1 g of L-hydroxyproline dissolved in 200 cc of 0.5 N methanolic sodium hydroxide, at ambient temperature 1525C). A further 200 cc of 0.5 N methanolic sodium hydroxide are then added during the course of half an hour. After stirring for a further half hour the product is left for one night at ambient temperature. The methanol is evaporated, brought up to the previous volume, with water, acidified with hydrochloric acid and extracted with ethyl acetate. After drying and evaporating the dinitrophenol derivative, crystallization is effected by the addition of ether.
13.1 g of the product are obtained.
Melting point l69l74C (with decomposition). a I062 Titer in acid: 99.6% The code number of this product is PC. 69-l3. The product has a formula:
HO T
EXAMPLE 2 N-(theophylline acetyl)-4-hydroxyl-L-proline sodium salt:
19.55 g of the hydrochloride of the methyl ester of L-hydroxyproline is dissolved in 400 cc of chloroform containing 28 cc of triethyl amine, the mixture is cooled to 0C. 25.65 g of theophylline acetyl chloride are introduced over a period of 10 minutes; the mixture is stirred for 30 minutes at 0C and then left for l hour at ambient temperature. Evaporation is effected under a vacuum. and triethyl amine hydrochloride is precipitated by acetone and then dried.
The acetone is evaporated and the residue heated to reflux in 200 cc of methanol containing 4 g of sodium hydroxide.
After half an hours of reflux the salt begins to precipitate; heating is continued for a further 45 minutes. The product is cooled, dried, and rinsed with methanol.
20 g of product are obtained.
Melting point: above 170C.
Sodium titer 202 The code number of this product is PC. 69-5.
The product has a formula:
COO Na.
EXAMPLE 3 N-acetyl-4-hydroxy-L-proline( m-trifluoromethyl anilide):
A solution of 400 mg of sodium nitrite in water is added slowly to a solution of N-acetyl-4-hydroxy-L- proline hydrazide l g) in IQ cc of acetic acid (10% by volume) in water at O2C, and the product stirred for 20 minutes at 0-5C. A solution of 2 cc of mtrifluoromethyl aniline in 2 cc of pyridine is then added and stirring continued for 30 minutes at O5C, then 2 hours at 20C.
The product is then acidified with 3N hydrochloric acid. allowed to stand for some hours, dried and crystallized with methanol -methylene chloride (Me-OH CH CL l g of product is obtained.
Melting point 2052lOC.
(01),, 46.7 in l% ethyl alcohol.
N-acetyl-4-hydroxy-L-proline (p-trifluoromethylanilide A solution of 400 mg of sodium nitrite in 2 cc of water is added slowly to a solution of l g of N-acetyl-4- hydroxy-L-proline hydrazide in 10 cc of IO% acetic acid in water at O-2C, the mixture is stirred for 20 minutes at 5C, after which a solution of 2 cc of ptrifluoromethyl aniline in 2 cc pyridine is added and stirring continued for 30 minutes at 05C, and then for 2 hours at 20C.
The product is then acidified with 3N hydrochloric acid, allowed to stand for some hours, dried and crystallized with methanol-methylene chloride (MeO- HCH,CI,).
l g of product is obtained.
Melting point 252C.
(01),, =-43 in ethyl alcohol.
The code number of this product is PC. 69-3.
The product has the formula:
O H t i' q 3 EXAMPLE 5 N -acetyl-0-( 4-isobutyl-phenyl-acetyl )-L- hydroxyproline:
200 cc of p-isobutyl-phenyl-acetyl chloride in 500 cc of CH Cl are added to I73 g of N-acetyl-L- hydroxyproline in 600 cc of pyridine cooled to 0C, in the course of half an hour, then the mixture is stirred for a further 30 minutes at 0C, after which the product is allowed to stand for 24 hours in a refrigerator.
After having been poured into the ice it is acidified till a pH of 2-3 is reached, using hydrochloric acid. The product is decanted, then extracted again with CH C1 (3 X 200 cc), the chloroformic phase is washed with water, and the product dried and evaporated. The product is crystallized by the addition of hexane, and 120 g of the product are obtained.
Melting point l 1 13C.
Acid titer 103% (01),, 31 in ethyl alcohol.
The code number of this product is PC. 69-7.
The product has the formula:
CH O ll GHCH H 0 -0 CH .COOH 3 EXAMPLE 6 N-(p-isobutyl-phenyl-acetyl)-4-hydroxy-L-proline)2 13.1 g of L-hydroxyproline are dissolved in 50 cc of water containing 4 g of sodium hydroxide at ambient temperature. 13 cc of the acid chloride is added fairly quickly, and then a further 50 cc of water containing 4 g of sodium hydroxide. The product is stirred until dissolution is complete, and allowed to stand for 1 hour, and is then acidified with 10% hydrochloric acid. The product is allowed to stand and is then dried.
The solid product is dissolved in CH,Cl dried over Na SO and concentrated, after which crystallization is carried out by adding hexane.
16.2 g of the product are obtained.
Melting point l30-132C.
(01),, =46 in ethanol.
The code number of this product is PC. 69-8.
The product has the formula:
\ OOH 9 2 /cH CH3 CH3 6 PHARMACOLOGICAL PROPERTIES Compounds prepared in accordance with the method of the invention have anti-inflammation properties, and are best described by taking for example PC. 68-9, or N-acetyl-4-hydroxyL-proline (m-trifluoromethyl anilide).
The usual tests on animals were employed to demonstrate anti-inflammation properties and in particular the RANDALL and SELlTTO test and the turpentine micro-abscess test.
1. In the RANDALL and SELIT'IO test inflammation is obtained by the injection under the plantar aponevrosis, of a 20% aqueous suspension of brewers yeast. A force is applied on the plantar surface which is gradually increasing by 16 g per second, and the threshold of pain is determined by the force necessary to initiate a characteristic withdrawal of the animal's paw.
The action of the PC. 68-9 is early and obvious in this test, the force required to initiate the withdrawal of the paw being almost double that in the case of the control animals. This action appeared as from the 30th minute.
The turpentine micro-abscess test technique is described in British Pat. No. 1,246,141. in this test the compounds forming the subject matter of this invention, and particularly PC. 68-9, exert a powerful action as from the 30 mg/kg dose. This action is associated with the reduction of reticulo-histiocytes, collagen fibres, fibroblasts and even the number of neovessels.
Furthermore the compounds of this series exhibit an analgesic activity in the test with 2-phenyl-1-4- benzoquinone in intraperitoneal injection.
To sum up, the pharmacological action of the derivatives of hydroxyproline forming the subject matter of this application consists of anti-inflammation action and an analgesic action.
it should also be noted a special activity of PC. 69-5 or the sodium salt of N-(theophylline acetyl)-4- hydroxy-L-proline, which is a very powerful cough cure (ammonia vapour test).
The products described above have been used on human beings in various ways suggested by the pharmacological data given, that is to say essentially the cases of rheumatism. lnvestigation on human beings confirm the results obtained with animals, demonstrating the activity of this range of products in various types of acute or chronic inflammatory rheumatism.
The various compounds forming the subject matter of this application have to be administered to human beings in doses each containing 0.100 g or 0.200 g of active product, in 3 to 8 doses a day, in any pharmaceutical form, preferably orally in the form of tablets or gelatin-coated pills.
EXAMPLES of pharmaceutical preparations Excipient quantity sufficient for 1 tablet. 3 to 8 tablets per day in the treatment of inflammatory cough affections of the respiratory passages.
The productions of the present invention may be used in any conventional acceptable pharmaceutical form for administration via digestive tract or for administration parenterally.
What we claim is:
l. A pharmaceutical composition suitable for antiinflammatory and analgesic use in dosage unit form comprising from I milligrams to 200 milligrams of a compound having the formula:
E LCD-R in which R is selected from the group consisting of OH.
m-trifluoromethylanilido and p-trifluoromethylanilido;
R isselected from the group consisting of acetyl, p-
isobutylphenylacetyl and 2,4-dinitrophenyl; R is hydrogen or p-isobutylphenylacetyl with the proviso that when R, is acetyl and R is hydrogen, then R cannot be OH; and a pharmaceutical carrier.
2. The composition of claim 1 in which the compound is N-acetyl-4-hydroxy-L-proline (ptrifluoromethyl anilide).
3. A method of reducing inflammation of connective tissue which comprises the oral or parenteral administration of the composition of claim I to animals in need thereof from three to eight times daily.
4. A method of reducing inflammation of human connective tissue which comprises the oral administration of the composition of claim 1 to humans in need thereof from three to eight times daily. l
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION PATENTNO. 3,891,765
DATED I June 2%, 1975 tNVENTOR(S) 1 Paul Col rre et al It is certified that error appears in the at10veidentitied patent and that said Letters Patent are heretry corrected as shown below:
Column 1, l ine 29, OH, should read R OH,
Column 3, l ine 39, hal f an hours" should read "half an hour".
Claim 3, l ines 1-2, "of connective tissue" should read "of animal connective tissue".
Signed and Scaled this A "es 2:
RUTH C. MASON C. MARSHALL DANN Arresting ()fj'icer (nmmr'ssimrer nf'lalenrs and Trademarks
Claims (4)
1. A PHARMACEUTICAL COMPOSTION SUITABLE FOR ANTI-INFLAMMATORY AND ANALGESIC USE IN DOSAGE UNIT FORM COMPRISING FROM 100 MILLIGRAMS TO 200 MILLIGRAMS OF ACOMPOUND HAVING THE FORMULA:
2. The composition of claim 1 in which the compound is N-acetyl-4-hydroxy-L-proline (p-trifluoromethyl anilide).
3. A method of reducing inflammation of connective tissue which comprises the oral or parenteral administration of the composition of claim 1 to animals in need thereof from three to eight times daily.
4. A method of reducing inflammation of human connective tissue which comprises the oral administration of the composition of claim 1 to humans in need thereof from three to eight times daily.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US243397A US3891765A (en) | 1967-09-14 | 1972-04-12 | Anti-inflammatory and analgesic L-hydroxyproline derivatives |
| US05/414,294 US3932638A (en) | 1967-09-14 | 1973-11-09 | Compositions and methods for wound healing |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR121020 | 1967-09-14 | ||
| FR152048A FR7639M (en) | 1967-09-14 | 1968-05-16 | |
| US8149970A | 1970-10-16 | 1970-10-16 | |
| US243397A US3891765A (en) | 1967-09-14 | 1972-04-12 | Anti-inflammatory and analgesic L-hydroxyproline derivatives |
| US05/414,294 US3932638A (en) | 1967-09-14 | 1973-11-09 | Compositions and methods for wound healing |
| US05/644,026 US3997559A (en) | 1967-09-14 | 1975-12-24 | N-acetyl-L-hydroxy-proline zinc salt |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US8149970A Continuation-In-Part | 1967-09-14 | 1970-10-16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/414,294 Continuation-In-Part US3932638A (en) | 1967-09-14 | 1973-11-09 | Compositions and methods for wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3891765A true US3891765A (en) | 1975-06-24 |
Family
ID=27546100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US243397A Expired - Lifetime US3891765A (en) | 1967-09-14 | 1972-04-12 | Anti-inflammatory and analgesic L-hydroxyproline derivatives |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3891765A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208421A (en) * | 1971-09-16 | 1980-06-17 | Lauzanne Morelle Eliane | Therapeutic compositions for the treatment of connective tissues diseases |
| WO1986007053A1 (en) * | 1985-05-20 | 1986-12-04 | Wilhelm Hoerrmann | Medicines which contain derivatives of proline or hydroxyproline |
| WO2002055073A1 (en) * | 2001-01-05 | 2002-07-18 | Kyowa Kakko Kogyo Co., Ltd. | Preventives for arthritis |
| US20070092472A1 (en) * | 2005-10-24 | 2007-04-26 | Kevin Meehan | Skin care composition for accelerated production of collagen proteins and method of fabricating same |
| US20080102042A1 (en) * | 2004-10-28 | 2008-05-01 | Kyowa Hakko Kogyo Co., Ltd. | Oral Composition |
-
1972
- 1972-04-12 US US243397A patent/US3891765A/en not_active Expired - Lifetime
Non-Patent Citations (4)
| Title |
|---|
| Chemical Abstracts 53:4259d-4260e (1959). * |
| Chemical Abstracts 58:3765h (1963). * |
| Chemical Abstracts 58:3773a (1963). * |
| J.A.C.S. 79 pp. 185-192, 1957 (Patchett et al). * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208421A (en) * | 1971-09-16 | 1980-06-17 | Lauzanne Morelle Eliane | Therapeutic compositions for the treatment of connective tissues diseases |
| WO1986007053A1 (en) * | 1985-05-20 | 1986-12-04 | Wilhelm Hoerrmann | Medicines which contain derivatives of proline or hydroxyproline |
| WO2002055073A1 (en) * | 2001-01-05 | 2002-07-18 | Kyowa Kakko Kogyo Co., Ltd. | Preventives for arthritis |
| US20040048772A1 (en) * | 2001-01-05 | 2004-03-11 | Ryusuke Nakagiri | Preventives for arthritis |
| US20080102042A1 (en) * | 2004-10-28 | 2008-05-01 | Kyowa Hakko Kogyo Co., Ltd. | Oral Composition |
| US20070092472A1 (en) * | 2005-10-24 | 2007-04-26 | Kevin Meehan | Skin care composition for accelerated production of collagen proteins and method of fabricating same |
| US7700083B2 (en) | 2005-10-24 | 2010-04-20 | Kevin Meehan | Skin care composition for accelerated production of collagen proteins and method of fabricating same |
| US20100120889A1 (en) * | 2005-10-24 | 2010-05-13 | Kevin Meehan | Skin care composition for accelerated production of collagen proteins and method of fabricating the same |
| US7914774B2 (en) | 2005-10-24 | 2011-03-29 | Kevin Meehan | Skin care composition for accelerated production of collagen proteins and method of fabricating the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS200455B2 (en) | Method of producing derivatives of benzoxazole | |
| JPH11500406A (en) | Acetamide derivatives and phagocytosis behavior modifiers | |
| PT96890B (en) | METHOD FOR PREPARING NEW DERIVATIVES WITH NAFTALENIC STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| IT9020562A1 (en) | ANTITUSSIVE AGENT AND MUCOREGULATOR, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS | |
| CZ286621B6 (en) | Tromethamine salt of (+)-(S)-2-(3-benzoylphenyl)propionic acid, process of its preparation and pharmaceutical preparation containing thereof | |
| US3624103A (en) | 3-indoleacetohydroxamic acids | |
| JPS58159458A (en) | Pyrrole acetic acid amide, manufacture and medicine | |
| US3489793A (en) | New benzamido butyric acid derivatives | |
| US3553258A (en) | Phenylalanine compounds | |
| US3891765A (en) | Anti-inflammatory and analgesic L-hydroxyproline derivatives | |
| JPH059424B2 (en) | ||
| EP0521393B1 (en) | Diclofenac choline salt, a method for the preparation thereof and pharmaceutical compositions containing it | |
| US3812109A (en) | Substituted indenyl glucoronide esters | |
| US4127671A (en) | P-acetamidophenyl diethylaminoacetate | |
| US3773936A (en) | Method of treating inflammation with substituted anilino salicylic acids | |
| PT90254B (en) | METHOD FOR PREPARING AMIDES OF CYCENOMETILENIC ACID-1,2-DICARBOXYL ACIDS WITH THERAPEUTIC ACTIVITY AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| US3466372A (en) | Treatment of inflammation with 4-phenyl - alpha - methyl - phenyl acetic acid,its salts,esters or amide derivatives | |
| US3769410A (en) | Tertiary amines with antalgic and antiinflammatory activity | |
| CZ182993A3 (en) | N-/(4,5-dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro - 9,10-dioxo-2-anthracenyl)carbonyl/ amino acids, process of their preparation and pharmaceutical preparations in which they are comprised | |
| JPH06500787A (en) | 5-aminosalicylic acid derivatives for the treatment of chronic inflammatory bowel disease | |
| US3763216A (en) | N-disubstituted derivatives of alpha-amino acids | |
| US3876683A (en) | (n-carboxymethyl)biphenyl acetamides | |
| US4122199A (en) | Amides of pyrrolidinoethylamine which can be used in treatment of coughs | |
| US2776993A (en) | 1-paramethoxyphenyl-2-cyclopentylamino-1-propanol compounds | |
| US3300510A (en) | Hydantoins |